Managing atypical hemolytic uremic syndrome: Chapter 2

Kidney International

Volumn 87, Issue 5, 2015, Pages 882-884

  Nester, Carla M ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

ANTIBODY TITER; CLINICAL TRIAL (TOPIC); COMPLEMENT ALTERNATIVE PATHWAY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE RESPONSE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; HUMANS; MALE;

EID: 84929085592     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.60     Document Type: Note

References (9)

1. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859.
2. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562.
3. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400.
4. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181.
5. Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87: 1061-1073.
6. Gerss JW, Kopcke W.. Clinical trials and rare diseases. Adv Exp Med Biol 2010; 686: 173-190.
7. Ariceta G, Besbas N, Johnson S et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696.
8. Taylor CM, Machin S, Wigmore SJ et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 148: 37-47.
9. Ardissino G, Testa S, Possenti I et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; 64: 633-637.